Engineering Molecular Glue Therapeutics Through Structure-Guided Design to Unlock Novel Targets & Accelerate Pipeline Progression

• Leveraging structural biology and computational modelling to systematically design and optimise molecular glue therapeutics
• Unlocking novel disease pathways by targeting proteins previously considered inaccessible to conventional drug discovery approaches
• Advancing a next-generation pipeline of molecular glue candidates through datadriven discovery and preclinical validation

Speakers:

Christian Ottmann

Founder & Chief Executive Officer

Ambagon Therapeutics